Targeted Oncology· @TargetedOnc · X·· 22 hours agoScore70
Body
An important question for KEYNOTE-B49 at #ESMO26:
KEYNOTE-756 is exploring pembrolizumab earlier in HR+/HER2− breast cancer.
If perioperative immunotherapy becomes standard, how relevant will B49 be to patients relapsing after prior PD-1 exposure?
B49 excluded these patients.
55 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.orgSource: Targeted Oncology · x.com